Healthcare -
Biotechnology - NASDAQ - US
$ 3.7
-5.13 %
$ 136 M
Market Cap
-1.71
P/E
1. INTRINSIC VALUE
Balance Sheet
Protara Therapeutics, Inc.
| Current Assets | 172 M |
| Cash & Short-Term Investments | 170 M |
| Receivables | 0 |
| Other Current Assets | 1.86 M |
| Non-Current Assets | 9.3 M |
| Long-Term Investments | 0 |
| PP&E | 5.28 M |
| Other Non-Current Assets | 4.02 M |
| Current Liabilities | 11 M |
| Accounts Payable | 4.43 M |
| Short-Term Debt | 1.12 M |
| Other Current Liabilities | 5.41 M |
| Non-Current Liabilities | 3.36 M |
| Long-Term Debt | 3.36 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Protara Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 49.2 M |
| Operating Income | -49.2 M |
| Other Expenses | -4.56 M |
| Net Income | -44.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Protara Therapeutics, Inc.
| Net Income | -44.6 M |
| Depreciation & Amortization | 332 K |
| Capital Expenditures | -63 K |
| Stock-Based Compensation | 4.12 M |
| Change in Working Capital | 4.01 M |
| Others | 2.95 M |
| Free Cash Flow | -35.9 M |
Wall Street Analysts Price Targets
Protara Therapeutics, Inc.
TARA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
TARA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Protara Therapeutics, Inc.
Sold
0-3 MONTHS
96.1 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
386 K USD 1
9-12 MONTHS
1.36 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
TARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA's pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives.
seekingalpha.com
- 3 weeks ago
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice Conference Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS), will be featured during an oral session at the American Society for Parenteral and Enteral Nutrition (ASPEN) 2025 Nutrition Science & Practice Conference, taking place March 22 through March 25, 2025 in Columbus, Ohio. Choline is an important substrate for phospholipids that are critical for healthy liver function.
globenewswire.com
- 1 month ago
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients by the end of 1H 2025 Cash, cash equivalents and investments of $170 million as of December 31, 2024, including gross proceeds from $100 million public offering in December 2024, expected to support planned operations into 2027 NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2024. “Following a year of significant progress and execution across our pipeline, we remain well positioned to deliver on our mission to bring transformative therapies to patients with cancer and rare diseases,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
globenewswire.com
- 1 month ago
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 9:50 am ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com.
globenewswire.com
- 1 month ago
Protara Highlights Recent Updates and Anticipated 2025 Milestones
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month evaluable NMIBC patients in ADVANCED-2 trial expected in mid-2025; Results from a futility analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 Results from additional cohorts of Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients expected by the end of 1H 2025 NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today highlighted recent updates and anticipated 2025 milestones. “Following a highly productive 2024 marked by positive data in our non-muscle invasive bladder cancer (NMIBC) program and with the funds from a successful financing, we are well positioned to accelerate our development programs and deliver on our mission to provide novel therapies to patients impacted by cancer and rare diseases,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
globenewswire.com
- 3 months ago
Protara Therapeutics: Rising From The Ashes
Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite recent stock fluctuations. The company raised $100M at $6.25 per share, ensuring a solid cash runway for potential Phase 3 trials and further development. Protara's current enterprise value is $70.2M, significantly undervalued compared to competitors like CG Oncology and Engene Holdings, indicating substantial upside potential.
seekingalpha.com
- 4 months ago
Protara Announces Closing of $100 Million Public Offering
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,690,000 shares of its common stock at a public offering price of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 2,402,305 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering were approximately $100 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters' option to purchase additional shares and the exercise of any pre-funded warrants. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.
globenewswire.com
- 4 months ago
Protara Therapeutics: Carving New Roads In Bladder Cancer
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potentially extending to 3-4 years with a $100 million capital raise. Despite positive early data, the small patient sample size necessitates caution; larger trials are needed to confirm efficacy and safety.
seekingalpha.com
- 4 months ago
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025.
seekingalpha.com
- 4 months ago
Protara Announces Pricing of $100 Million Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,690,000 shares of its common stock at a price to the public of $6.25 per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of $6.249 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 2,402,305 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares and pre-funded warrants in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters' option to purchase additional shares and the exercise of any pre-funded warrants. The offering is expected to close on December 11, 2024, subject to satisfaction of customary closing conditions. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.
globenewswire.com
- 4 months ago
Protara Announces Proposed Public Offering
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by Protara. In addition, Protara expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.
globenewswire.com
- 4 months ago
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
zacks.com
- 4 months ago
8. Profile
Summary
Protara Therapeutics, Inc. TARA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 136 M
Dividend Yield
0.00%
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Contact
345 Park Avenue South, New York, NY, 10010
https://www.protaratx.com
IPO
Date
Oct. 22, 2014
Employees
28
Officers
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.
Co-Founder, Senior Vice President & Chief Scientific Operations Officer
Ms. Hannah Fry
Vice President, Principal Accounting Officer & Controller
Mr. Jesse Shefferman
Co-founder, Chief Executive Officer, President & Director
Mr. Patrick Fabbio M.B.A.
Chief Financial Officer
Ms. Mary J. Grendell J.D.
General Counsel & Corporate Secretary
Ms. Justine O'Malley
Senior Vice President of Investor Relations & Corporate Affairs